Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and chronic kidney disease. Based on FLOW trial data, Novo Nordisk submitted a label extension application for…